BioCryst Pharmaceuticals, Inc. (BCRX) Deep Dive Video

A newly profitable rare-disease franchise built on ORLADEYO’s oral convenience is evolving into a multi-asset HAE platform—if navenibart delivers and competition doesn’t force the market to “inject for efficacy.”